Search

Search Constraints

You searched for: Author/Creator Fasching, Peter A.

Search Results

41. Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab. Issue 6 (June 2018)

42. Identification of New Genetic Susceptibility Loci for Breast Cancer Through Consideration of Gene‐Environment Interactions. Issue 1 (18th November 2013)

43. Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. (February 2018)

44. Incorporating progesterone receptor expression into the PREDICT breast prognostic model. (September 2022)

45. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. (December 2020)

46. Interest in Integrative Medicine Among Postmenopausal Hormone Receptor–Positive Breast Cancer Patients in the EvAluate-TM Study. (June 2017)

47. Investigation of gene‐environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors. Issue 6 (23rd September 2014)

48. Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair. Issue 12 (December 2015)

49. Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials. (May 2020)

50. Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial. (October 2022)